Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies.
Claus BachertAnju T PetersEnrico HefflerJoseph K HanHeidi OlzeOliver PfaarChien-Chia ChuangRaj RoutRicha AttreLedia GogaJuby A Jacob-NaraPaul J RoweYamo DenizZhen ChenSiddhesh KamatShahid SiddiquiPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022)